Methods for treating HCV
DCFirst Claim
Patent Images
1. A method of treatment for HCV, comprising administering at least two direct acting antiviral agents (DAAs) and ribavirin to an HCV treatment-naï
- ve patient infected with HCV genotype 1, wherein said treatment does not include administration of interferon to said patient, and said treatment lasts for 8 weeks, wherein said at least two DAAs comprise Compound 1
0 Assignments
Litigations
0 Petitions
Accused Products
Abstract
The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin.
198 Citations
20 Claims
-
1. A method of treatment for HCV, comprising administering at least two direct acting antiviral agents (DAAs) and ribavirin to an HCV treatment-naï
- ve patient infected with HCV genotype 1, wherein said treatment does not include administration of interferon to said patient, and said treatment lasts for 8 weeks, wherein said at least two DAAs comprise Compound 1
- View Dependent Claims (2, 3, 4, 5)
-
6. A method of treatment for HCV, comprising administering at least two direct acting antiviral agents (DAAs) and ribavirin to an HCV treatment-naï
- ve patient infected with HCV genotype 1, wherein said treatment does not include administration of interferon to said patient, and said treatment lasts for 8 weeks, and wherein said at least two DAAs comprise PSI-7977 and GS-5885.
- View Dependent Claims (7, 8, 9, 10, 11)
-
12. A method of treatment for HCV, comprising administering at least two direct acting antiviral agents (DAAs) and ribavirin to an HCV treatment-naï
- ve patient infected with HCV genotype 1, wherein said treatment does not include administration of interferon to said patient, and said treatment lasts for 8, 9, 10, 11 or 12 weeks, and wherein said at least two DAAs comprise Compound 1, Compound 2 and Compound 4, or said at least two DAAs comprise PSI-7977 and GS-5885.
- View Dependent Claims (13, 14, 15, 16, 17, 18, 19, 20)
Specification